Trial Profile
A Phase Ia Dose-escalation Study to Access the Tolerability Safety Pharmacokinetics and Pharmacodynamics of Recombinant Human Thrombopoietin in the Patients With Different Degree of Liver Function Impairment
Status:
Recruiting
Phase of Trial:
Phase 0
Latest Information Update: 07 Mar 2022
Price :
$35
*
At a glance
- Drugs Thrombopoietin (Primary)
- Indications Aplastic anaemia; Idiopathic thrombocytopenic purpura; Thrombocytopenia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Shenyang Sunshine Pharmaceutical
- 20 Mar 2020 Planned End Date changed from 31 Dec 2019 to 31 Dec 2020.
- 20 Mar 2020 Planned primary completion date changed from 31 Jul 2019 to 8 Oct 2020.
- 25 Sep 2018 New trial record